TIMER2 suggested that the RBM10 expression was closely correlated with the infiltration levels of B cells in 14 types of cancer, CD8+ T cells in 22 types of cancer, CD4+ T cells in 18 types of cancer, neutrophils in 21 types of cancer, myeloid dendritic cells in 22 types of cancer, and macrophages in 19 types of cancer (Figure 5(a)). This evidence concerns the gene RBM10 and cancer.